Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab Extension Study in CNV Secondary to AMD
NCT00504959Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2007
- Primary completion
- Jan 2010
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 4 trial of ranibizumab in neovascular age-related macular degeneration (NVAMD), sponsored by Novartis. Started Jul 2007; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00504959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00504959.